Nasdaq · CIK 0001835654
INVZ Innoviz Technologies Ltd.
Insider trading from SEC Form 4. Last filing Aug 5, 2026.
In brief
Innoviz Technologies Ltd. (INVZ) has 15 SEC Form 4 filings on file from 14 insiders, the latest filed on Aug 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 Form 144 notices of planned sales are on file, the latest filed Sep 22, 2025.
Last 90 days
Signals
Open-market buys and sells at Innoviz Technologies Ltd., scored.
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 22, 2025 | Cegla Eldar Mordechay Officer | 4,292 0.00% of outstanding | $8,455 | Sep 19, 2025 | $7,450 |
| Dec 26, 2024 | Cegla Eldar Mordechay Officer | 10,000 0.01% of outstanding | $15k | Dec 24, 2024 | none |
| Feb 28, 2024 | Cegla Eldar Mordechay Officer | 5,000 0.00% of outstanding | $8,100 | Feb 27, 2024 | $9,251 |
Transactions
Every row filed, 23 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Even Yoav Har director | AGrant or award Ordinary Shares | +90,162 | $0.00 | $0 | 90,162 | Aug 5, 2026 |
| Aug 4, 2026 | Elad Ben Hofstetter Chief Business Officer | AGrant or award Ordinary Shares | +54,112 | $0.00 | $0 | 286,256 | Aug 5, 2026 |
| Aug 4, 2026 | Avishay Ben Moscovici Chief R&D Officer | AGrant or award Ordinary Shares | +66,336 | $0.00 | $0 | 397,001 | Aug 5, 2026 |
| Aug 4, 2026 | Ido Luski Chief Operating Officer | AGrant or award Ordinary Shares | +64,688 | $0.00 | $0 | 393,701 | Aug 5, 2026 |
| Aug 4, 2026 | Eldar Mordechay Cegla Chief Financial Officer | AGrant or award Ordinary Shares | +73,184 | $0.00 | $0 | 537,237 | Aug 5, 2026 |
| Aug 4, 2026 | Eldar Mordechay Cegla Chief Financial Officer | AGrant or award Share Optionderivative | +78,416 | $0.00 | $0 | 78,416 | Aug 5, 2026 |
| Aug 4, 2026 | Elad Ben Hofstetter Chief Business Officer | AGrant or award Share Optionderivative | +57,968 | $0.00 | $0 | 57,968 | Aug 5, 2026 |
| Aug 4, 2026 | Avishay Ben Moscovici Chief R&D Officer | AGrant or award Share Optionderivative | +71,072 | $0.00 | $0 | 71,072 | Aug 5, 2026 |
| Aug 4, 2026 | Ido Luski Chief Operating Officer | AGrant or award Share Optionderivative | +69,296 | $0.00 | $0 | 69,296 | Aug 5, 2026 |
| Jul 7, 2026 | Omer David Keilaf Chief Executive Officer | JOther Ordinary Shares | -679,400 | $0.00 | $0 | 2,826,531 | Jul 9, 2026 |
| Jul 7, 2026 | Omer David Keilaf Chief Executive Officer | JOther Share Optionderivative | -510,222 | $0.00 | $0 | 510,222 | Jul 9, 2026 |
| Jul 7, 2026 | Omer David Keilaf Chief Executive Officer | JOther Share Optionderivative | -342,408 | $0.00 | $0 | 342,408 | Jul 9, 2026 |
| Jul 7, 2026 | Omer David Keilaf Chief Executive Officer | JOther Share Optionderivative | -29,240 | $0.00 | $0 | 64,328 | Jul 9, 2026 |
| Jul 7, 2026 | Omer David Keilaf Chief Executive Officer | JOther Share Optionderivative | -25,641 | $0.00 | $0 | 91,575 | Jul 9, 2026 |
| May 13, 2026 | Aharon Aharon director | AGrant or award Ordinary Shares | +110,668 | $0.00 | $0 | 344,997 | May 15, 2026 |
| May 13, 2026 | Dan Michael Falk director | AGrant or award Ordinary Shares | +110,668 | $0.00 | $0 | 344,997 | May 15, 2026 |
| May 13, 2026 | Alexander Reymar Karl-Wilhelm Von Witzleben director | AGrant or award Ordinary Shares | +110,668 | $0.00 | $0 | 296,768 | May 15, 2026 |
| May 13, 2026 | Amichai Steimberg director | AGrant or award Ordinary Shares | +265,602 | $0.00 | $0 | 989,336 | May 15, 2026 |
| May 13, 2026 | James J. Sheridan III director | AGrant or award Ordinary Shares | +110,668 | $0.00 | $0 | 427,397 | May 15, 2026 |
| May 13, 2026 | Orit Stav director | AGrant or award Ordinary Shares | +110,668 | $0.00 | $0 | 344,997 | May 15, 2026 |
| May 13, 2026 | Shenaar Ronit Maor director | AGrant or award Ordinary Shares | +110,668 | $0.00 | $0 | 344,997 | May 15, 2026 |
| May 13, 2026 | Stefan Jacoby director | AGrant or award Ordinary Shares | +110,668 | $0.00 | $0 | 291,994 | May 15, 2026 |
| Apr 30, 2026 | Omer David Keilaf Chief Executive Officer | JOther Ordinary Shares | -723,019 | $0.00 | $0 | 3,505,931 | May 4, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Aharon Aharondirector
- Eldar Mordechay CeglaChief Financial Officer
- Dan Michael Falkdirector
- Even Yoav Hardirector
- Elad Ben HofstetterChief Business Officer
- Stefan Jacobydirector
- Omer David KeilafChief Executive Officer
- Ido LuskiChief Operating Officer
- Shenaar Ronit Maordirector
- Avishay Ben MoscoviciChief R&D Officer
- James J. Sheridan IIIdirector
- Orit Stavdirector
- Amichai Steimbergdirector
- Alexander Reymar Karl-Wilhelm Von Witzlebendirector
Questions about INVZ
Answered from the filings on this page, as of the latest one.
Are insiders buying INVZ?
No. In the last 90 days no insider at Innoviz Technologies Ltd. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade INVZ on the open market?
No open-market trade has been scored at Innoviz Technologies Ltd.. The latest Form 4 on file was filed on Aug 5, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Innoviz Technologies Ltd.?
14 people have filed a Form 4 at Innoviz Technologies Ltd., among them Aharon Aharon (director), Eldar Mordechay Cegla (Chief Financial Officer), Dan Michael Falk (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.